Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Total Liabilities: 2019-2024

Historic Total Liabilities for Allogene Therapeutics (ALLO) over the last 6 years, with Dec 2024 value amounting to $126.5 million.

  • Allogene Therapeutics' Total Liabilities fell 0.74% to $124.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $124.4 million, marking a year-over-year decrease of 0.74%. This contributed to the annual value of $126.5 million for FY2024, which is 3.12% down from last year.
  • As of FY2024, Allogene Therapeutics' Total Liabilities stood at $126.5 million, which was down 3.12% from $130.6 million recorded in FY2023.
  • In the past 5 years, Allogene Therapeutics' Total Liabilities registered a high of $154.7 million during FY2022, and its lowest value of $125.6 million during FY2021.
  • Its 3-year average for Total Liabilities is $137.3 million, with a median of $130.6 million in 2023.
  • As far as peak fluctuations go, Allogene Therapeutics' Total Liabilities surged by 66.94% in 2020, and later dropped by 15.57% in 2023.
  • Allogene Therapeutics' Total Liabilities (Yearly) stood at $148.2 million in 2020, then dropped by 15.24% to $125.6 million in 2021, then increased by 23.14% to $154.7 million in 2022, then fell by 15.57% to $130.6 million in 2023, then dropped by 3.12% to $126.5 million in 2024.